secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001193125-25-289713
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma CMO Matteo Levisetti to depart Nov 28; gets $556,838 severance
----------------------------------------------------------------------------

- Chief Medical Officer Matteo Levisetti will terminate employment effective November 28, 2025.
- Severance includes lump sum of $556,837.60 (nine months base salary plus prorated 2025 bonus).
- COBRA premiums paid by company for up to nine months post-separation if elected.
- Payment conditioned on execution and nonrevocation of a separation and release agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525289713/0001193125-25-289713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525289713/cue-20251117.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-289713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer